Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for June 2008
June 2, 2008
- Acorda Therapeutics Announces Positive Data from Second Phase 3 Study of Fampridine-SR on Walking Ability in People with Multiple Sclerosis
- BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
- Apthera's NeuVax Produces Delays in Recurrence in High-Risk HER2-Positive Prostate Cancer Patients
- Antisoma plc (UK) - Positive data on Antisoma's ASA404 presented at ASCO
- CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
- Clavis Pharma ASA (NO) - Elacyt Clinical Results Presented at ASCO
- Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
- Data Presented at ASCO Identify Maximum Tolerated Dose and Confirm c-Met Inhibition in Tumors with ARQ 197, Under Development by ArQule
- Data Confirm Avastin Helps Patients With Metastatic Colorectal Canc...
- Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Used in Combination With Ipilimumab
- Transgene’s Therapeutic Vaccine TG4010 Meets Primary Endpoint in Non-small Cell Lung Cancer Phase IIb Trial
- Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
- Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
- Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa in Women With Early-Stage Breast Cancer
- Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO Annual Meeting
- Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara for the Treatment of Brain Cancer
- Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women with Advanced HER2-Negative Breast Cancer
- YM Biosciences Reports Nimotuzumab Nsclc Clinical Data at ASCO Annual Meeting
- Velcade (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
- Xencor to Present New Data from Anti-CD19 Antibody Program at ASCO
- Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix (panitumumab) in Combination with Standard Chemotherapy
- Combination Therapy of Solvent-free Abraxane and the Targeted Therapy Bevacizumab Evaluated as First-line Treatment for Metastatic Breast Cancer
- Updated Revlimid Results Presented In Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) at ASCO
- ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642
- Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
- Novo Nordisk and Neose Announce Completion of Initial Phase 1 Clinical Trial of NN7128 (Long-Acting Factor VIIa)
- EntreMed's ENMD-2076 Demonstrates Antitumor Activity in Multiple Myeloma Model
- Genta Announces Initial Clinical Trial Results for G4544, a Novel Potent Drug for Bone Disease
- Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
- PsychoGenics Announces Positive Phase-IIa for Its First-in-Class Partial 5-HT1A - 5-HT1B Receptor Agonist in ADHD
- Sanofi-aventis and Oxford Biomedica Report Encouraging Trovax Phase II Trial Results in Metastatic Renal Cancer
- Gloucester Pharmaceuticals Announces Presentation of Romidepsin Phase 1 Data in Multiple Solid Tumors at ASCO
- Adherex Announces Updated ADH-1 Chemotherapy Combination Data in Melanoma
- Curis Announces GDC-0449 Phase I Clinical Data Presented at American Society of Clinical Oncology Annual Meeting 2008
- New Data Show Patients Using Avonex Reported Less Sick Leave and Short-Term Disability Costs Than Patients Using Copaxone
- CytRx to Present Favorable Study Data with Iroxanadine in Diabetic Wound Healing at the Third Congress of the World Union of Wound Healing Societies
- New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar's Innovative Small Molecule PEG-Oncolytics
- Oculus Innovative Sciences Announces Market Assessment of Near-Term Commercialization Opportunities in the United States for Dermacyn Wound Care
- Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
- Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
- Incyte's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits in Ongoing Phase I/II Myelofibrosis Study
- VioQuest Pharmaceuticals Presents Phase 1 Data Showing Promising Immune Response and Safety Profile of Lenocta
- Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
- Exelixis Reports Phase 1 and Phase 2 Data For XL647 at ASCO
- Combination Therapy of Solvent-Free Abraxane and the Targeted Therapy Bevacizumab Evaluated as First-Line Treatment for Metastatic Breast Cancer
- Abraxane in Combination with Trastuzumab and Carboplatin Evaluated as First-Line Treatment for Patients with HER2-Positive Metastatic Breast Cancer
- TransMolecular Reports Positive Results from Phase 1 Trial of (131)Iodine-TM601 in Metastatic Melanoma
- Molecular Insight Pharmaceuticals, Inc. Reports Preliminary Results of Azedra Phase I Trial in Neuroendocrine Cancer Patients at ASCO
- Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
- Anti-TGF-Beta Antisense AP 12009 Shows Very Good Safety and Tolerability in Systemic Treatment of Pancreatic Carcinoma, Malignant Melanoma and Colorectal Carcinoma
- Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
- Lung Cancer Alliance Hails Announcement of New Erbitux Data
- Novelos Announces Presentation of Encouraging Results in Phase 2 Ovarian Cancer Trial at 2008 ASCO Meeting by MGH and Dana-Farber/Harvard Cancer Centers
- New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
- Schering-Plough's Sugammadex Provides Fast Reversal of Effects of Muscle Relaxants Used in General Anesthesia
- IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
- University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
- Study Suggests Survival Benefit from Radioactive Microsphere Therapy in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy
- Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
- Stimuvax Phase 1/2 Survival Data Support Prior Results
- New Publication of Phase 2 Data Shows Maribavir Markedly Reduced the Rate of Cytomegalovirus Infection and Disease in Bone Marrow Transplant Patients
- BiPar Sciences Presents Initial Clinical Data of BSI-201, a Novel DNA Repair Inhibitor
- Researchers at Signature Characterize Previously Unreported Microduplication
- Ipsen and Spirogen's SJG-136 Shows Encouraging Results in the Treatment of Refractory Solid Tumours At ASCO
- OncoGenex Reports that Low Serum Clusterin Levels were Predictive of Survival in Preliminary Analyses of Phase 2 Study of Lead Drug Candidate OGX-011
- Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
- Geron Presentations at the ASCO 2008 Annual Meeting
- Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting
- Vidaza Data Presented at ASCO Demonstrates Significant Overall Survival for Myelodysplastic Syndrome Patients
- Metformin Increases Pathologic Complete Response Rates in Breast Cancer Patients With Diabetes
- Hana Reports Progress in Phase 2 Uveal Melanoma Trial
- Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase I and Phase II Data at ASCO 2008 Annual Meeting
- Investigational Studies Highlight Potential Utility of Zevalin (Ibritumomab Tiuxetan) Radioimmunotherapy in Stem Cell Transplantation for Non-Hodgkin's Lymphoma
- New Data from Several Satraplatin Clinical Trials in Solid Tumors Presented at 44th ASCO Annual Meeting
- Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
- Data Presented at This Year's ASCO Meeting Provide New Insights into the Treatment of Patients with Myelodysplastic Syndromes
- Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
- US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
- Nimotuzumab Clinical Data Presented at ASCO Annual Meeting
- Methylgene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
- Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
- Early Data Presented at ASCO Show Potential of RAD001 To Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
- Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
- Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
- IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE)
- Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine (VNP40101M) in Acute Myelogenous Leukemia at the ASCO Annual Meeting
- Leading Immunologists Convene in Boston
- Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
June 3, 2008
- Trubion Announces Presentation of Positive TRU-016 Data at ASCO
- Paclitaxel Poliglumex (Opaxio)/Capecitabine Regimen Well Tolerated and Active in Metastatic Breast Cancer
- ChemGenex Investigators Present Data on Clinical Activity of Omacetaxine in Imatinib-Resistant Chronic Myeloid Leukemia Patients with the T315I Mutation at ASCO
- New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing's Sarcoma
- Critical Therapeutics Completes Phase II Clinical Trial for Zileuton Injection
- Data from Studies of Amrubicin in Small-Cell Lung Cancer Presented at the 2008 American Society of Clinical Oncology Meeting Demonstrate Single Agent Anti-Tumor Activity in Western Patient Population
- Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
- Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
- Analysis Showed No Increased Risk of Hospitalization in Patients When Adding a LABA to ICS Compared to ICS Alone
- ThromboGenics and BioInvent Report Positive Phase I Results for Anti-PlGF Cancer Therapeutic TB-403
- ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
- Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL
- Auxilium Pharmaceuticals, Inc. Announces Xiaflex Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
- The Aethlon Hemopurifier Proves Effective in Capturing the Reconstructed Spanish Flu of 1918 and H5N1 Avian Influenza Virus
- The GI Company Reports Significant Reduction in Occurrence of Oral Mucositis in Phase II Study Presented at ASCO
- EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
- Tolerx Announces Data Presentations at American Diabetes Association 68th Scientific Sessions 2008
- Study of Vidaza in Higher-Risk Myelodysplastic Syndrome Patients Demonstrates Improved Overall Survival
- Zysolin Shows Promising Results in Animal Study
- NexMed Confirms Publication on Anti-Fungal Product
- Isotechnika To Hold Conference Call to Discuss Positive PROMISE Trial
- Transgene’s Therapeutic Vaccine TG4010 Meets Primary Endpoint Non-small Cell Lung Cancer Phase IIb Trial
- Virax Co-X-Gene Technology Licence with Transgene Successful Phase IIb trial Result for TG4010 in Non-Small Cell Lung Cancer
- Altus Pharmaceuticals Reports ALTU-237 Phase 1 Clinical Trial Results
- Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
- New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting
- Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma
- ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO
- ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO
- Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
- Generex Biotechnology Phase I Trial Results for Novel Immunotherapy Vaccine in Breast Cancer Patients Presented at ASCO
- Immtech Announces Results From Hepatitis C Discovery Program
- On Matters of the Heart, Women Aged 40-plus Naive When It Comes to Risks
- New Modified Citrus Pectin Slows Cancer Progression and Stops Cancer Cells in Their Tracks
- AVAX Presents Results of a Dose-Response Study of MVax at American Society of Clinical Oncology (ASCO)
- Newly Published Study Shows OPKO's siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
- Promising Data on Head and Neck Cancer Announced by DNAR at 2008 American Society of Clinical Oncology Meeting
June 4, 2008
- Akesis Pharmaceuticals Completes Phase IIa Trial of AKP-020 for Type 2 Diabetes
- Reduced Hepatitis C Viral Level Achieved with DNA Vaccine Delivered by Inovio Biomedical's Electroporation Delivery System in Phase I/II Clinical Study
- NanoViricides Inc. to Present at The NSTI Nanotech 2008 Conference in Boston
- Celator Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
- VIVUS Announces the Podium Presentation of Phase 2 Data for Qnexa in Type 2 Diabetics at the American Diabetes Association Meeting
- Sirtris Pharmaceuticals Presents at the American Diabetes Association's 68th Annual Scientific Sessions June 8
- Isotechnika Presents Positive Data from the Promise Trial of Voclosporin at the American Transplant Congress
- Interim Phase 2 Results on Prospect Therapeutics' GCS-100 Presented at the 10th International Conference on Malignant Lymphoma
- Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo in Third Quarter 2008
- Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference
- Intravenous Iron May Help Treat Anemia in Patients with Kidney Disease
- Somaxon Pharmaceuticals to Present Data at the 22nd Annual Meeting of the Associated Professional Sleep Societies
- Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
- CellCept and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
- World's Leading Health Experts Urge Countries to Use Newly Released Data to Prevent the Death of Millions of Children Due to Rotavirus
- New Diabetes Research To Be Presented at FOCIS Annual Meeting
- World's Leading Health Experts Urge Countries to Use Newly Released Data to Prevent the Death of Millions of Children Due to Rotavirus
- Racial Disparities in the Outcomes of Patients with Chronic Kidney Disease Abound
June 5, 2008
- Promise of Vical's CMV Vaccine Noted by Independent Experts
- Inovio Biomedical Provides Updated Interim Data on Phase I/II Clinical Study of Electroporation-Delivered Prostate Cancer DNA Vaccine at ASGT Annual Meeting
- Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
- Arana Therapeutics Completes Second Project with CSL
- Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma
- Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
- SPP100 (Tekturna/rasilez) Demonstrates Potential to Protect Kidneys from Damage
- Positive Clinical Data Evaluating the Micrus Endovascular Cerecyte Microcoil Published in Peer-Reviewed Journals
- SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
- Ardea to Present Data on Inflammation Programs at 2008 Annual European Congress of Rheumatology
- MacroChem Announces Presentation by Michael Zasloff, MD, PhD on Topical Therapy for Diabetic Foot Infection
- Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkin's Lymphoma
- Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program
- Senesco Expands on Preclinical Multiple Myeloma Findings
- Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma
- Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma
- New Data Show Potential of Rasilez to Protect Kidneys from Damage Independent of Its Proven Ability to Lower Blood Pressure
- Study Supports Possible Use of Leukine as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
- Gloucester Pharmaceuticals Announces Podium Presentation of Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
- Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer
June 6, 2008
- TriMix Gel Achieves Success Among Men Who Have Failed to Achieve Erections With Viagra, Levitra and Cialis Type Tablets
- Allos Therapeutics Announces Interim Data from Phase 1 Study of PDX in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma
- T3Therapeutics, LLC and Archimedes Pharma Ltd Announce Positive Clinical Results for Novel Oral Modified Release Liothyronine
- Inspire Announces Achievement of Primary Endpoint in Phase 3 Trial with Denufosol for Cystic Fibrosis
- Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 3rd International Workshop on Hepatitis C, Resistance and New Compounds
- Seattle Genetics Announces SGN-35 Plenary Presentation at International Conference on Malignant Lymphoma
- Brain Stem Cells Can Be Awakened, Say Schepens Scientists
- Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
- CONTRAST Study: To What Extent Do High-Risk Patients Benefit From the Renal Tolerance of Iso-Osmolar X-Ray Contrast Media?
June 9, 2008
- ImmuneRegen BioSciences Confirms Adult Stem Cell Activity of Homspera in Human Bone Marrow
- Repros Therapeutics Inc. Announces That Initial Findings for Proellex Show No Gross Cancer Tumors in First Completed Animal Carcinogenicity Study
- Achillion Announces Additional Positive Top-Line Phase 2 Data for Elvucitabine
- Accord Clinical Trial Publishes Results
- Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix in Combination with Crestor Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
- Onglyza (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes
- NanoViricides Inc. Posts Photos Showing Rapid Response of Animals to Treatment with EKC Eye Drug Candidate
- Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with Triolex Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes
- Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting
- Cerus Announces INTERCEPT Blood System Data Presented at International Society of Blood Transfusion Conference Support Broad Utility in Safeguarding the Blood Supply
- Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
- Arisaph Pharmaceuticals Announces at the ADA that Its Potent DPP 4 Inhibitor (ARI-2243) Possesses an Additional Mechanism that Contributes to Improved Glucose Control
- Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
- Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment
- Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
- Elixir Pharmaceuticals Announces New Data at the 2008 American Diabetes Association Annual Meeting
- Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
- Data from Phase II Clinical Trial of Galiximab in Combination with Rituximab in Patients with Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma
- Generex Biotechnology Presented Data At American Diabetes Association Scientific Sessions
- Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
- Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting
- Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R and with Humalog Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
- Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
- Biopure Responds to JAMA and Meta-Analysis
- Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Models of Lung Inflammation and Psoriasis
- A New Analysis Released at ADA: Lower Risk of Symptomatic Hypoglycemia with Januvia (sitagliptin) Compared to Glipizide on a Background of Metformin in Patients with Type 2 Diabetes
- Lipid Sciences' Autologous Therapeutic HIV Vaccine Study Published in "Experimental Biology and Medicine"
- Kamada Announces Successful Interim Results of Phase II Deposition Study with Aerosolized AAT
- Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with Triolex Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes
- New Discovery of Key Difference in Bile Acid Metabolism in Patients with Type 2 Diabetes May Suggest Underlying Disorder
- CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
- Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO
June 10, 2008
- Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
- Alexza Announces Preliminary Results From its AZ-002 (Staccato Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
- OSI Pharmaceuticals Presents Diabetes/Obesity Preclinical Compounds, PSN821 and PSN602, at Annual Meeting of the American Diabetes Association
- Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials
- After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
- Use of Mealtime Symlin Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
- Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2
- Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics
- Schizophrenia: Twice as Common as HIV/AIDS, but Survey Shows Americans Misinformed
- High-dose Immunosuppressant Drug Appears to Reduce Disease Activity and Disability in Patients with Multiple Sclerosis
- NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
- Acomplia (rimonabant) Significantly Improved Glucose Control in Type 2 Diabetes Patients Treated with Insulin
- Five-Year Safety Study Examines the Effect of LANTUS® on the Progression of Retinopathy in People with Type 2 Diabetes
- Metabasis Presents Preclinical Results for MB07803, Its Product Candidate for Type 2 Diabetes, and Its Glucagon Antagonist Program at the American Diabetes Association Meeting
- Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
- Results From One-Year Study Suggest Advair Provides Important Benefits for African American Patients With Asthma
- Qnexa Reduces Hemoglobin A1c by 1.2 Percent in 28 Weeks
- After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
- Ambien CR (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
- Array BioPharma to Present Clinical Data at the 2008 Annual European Congress of Rheumatology
June 11, 2008
- Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
- Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
- Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID, which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
- Panacos Presents Bevirimat Patient Response Predictors at the International HIV Drug Resistance Workshop
- Pierre Fabre Medicament Announces Submission of a Market Authorization Application for Milnacipran in Europe : New Data from European Phase III Fibromyalgia Study presented at EULAR congress
- Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
- CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
- New evidence shows MabThera is more effective than a second TNF inhibitor in rheumatoid arthritis patients who have interrupted anti-TNF therapy due to lack of efficacy
- New potential application for SUBA-Itraconazole in oncology
- Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
- Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
- Diabetes Experts Respond to New Clinical Trials
- Optimer to Present Additional Data from OPT-80 Phase 2A Study for Clostridium difficile Infection at Anaerobe 2008 Congress
- New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
- Novo Nordisk Discontinues Phase 3 Clinical Trial with Novoseven in Trauma
- Interim Results for the Zilver PTX Clinical Study from Cook Medical Show Promise for Improving the Treatment of Blockages in the Femoropopliteal Artery
- Intermezzo 3.5 mg Achieves Greater Early Bioavailability Than Ambien 10 mg Despite 65% Lower Dose
- Angiotech's Corporate Partner, Cook Medical, Announces Positive Interim Results for its Zilver PTX Clinical Study
- MTR106 Tablets Were Found to be Effective in Acute Migraine Attacks
June 12, 2008
- The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
- Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
- Incyte to Host EULAR Webcast and Conference Call on June 12
- Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study
- Promising Data Presented on GenVec Malaria Vaccine Program
- Dermatologic Surgery Journal Publishes Comparison of Global PMMA-Based Dermal Fillers Showing Superior Characteristics of ArteFill Microspheres
- EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
- Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers’ Diarrhea Vaccine
- Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
- Ambrilia Biopharma Presents New HIV Integrase Inhibitors
- Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
- Geron Presents Data at ISSCR Showing That Its Embryonic Stem Cell Therapeutic for Heart Failure Evades Direct Attack by the Human Immune System
- Pharmaxis Long-Term Safety Study of Bronchitol Completes
- Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
- BioSante Pharmaceuticals VP of Clinical Development To Present at The Endocrine Society's 90th Annual Meeting
- Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
- Orencia (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
- Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin for Multiple Sclerosis
- Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
- Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
- PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
- Tumor Targeting Docetaxel Abstract Selected for Presentation at the 11th Liposome Research Days Conference
- SILENOR Data Presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies
- At Least 50% of Recent Onset Rheumatoid Arthritis Patients Become Free of Signs and Symptoms Within 36 Weeks
- New Self-Management Programme Offers Significant Benefits for Arthritis Patients with Chronic Pain
- Inspire's Phase 3 CF Trial, Using PARI's Nebulizer & Compressor, Shows Positive Top-Line Results
- Adalimumab Therapy Effective in Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Refractory to Other Anti-tnf Therapies
- Hand Bone Mineral Density is an Effective Predictor of Mortality in Rheumatoid Arthritis
- Ovarian Function and Fertility Preserved in Women with Severe Systemic Lupus Erythematosus Through Treatment with Cyclophosphamide and Mycophenolate Mofetil
June 13, 2008
- NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
- Acterma (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
- Vion Pharmaceuticals Announces Presentation of Data of Cloretazine (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
- New Long-Term Humira (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
- Humira (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
- Data Show that Abbott's Humira (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
- Array BioPharma Presents Additional Positive Phase 1 Results in Two Programs at the 2008 Annual European Congress of Rheumatology
- New data: Actemra the first and only biologic to show superiority over current standard of care in RA
- NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
- Higher Initial Dose of Glivec Achieved Better Early Responses Than Standard Dose for Patients with Chronic Myeloid Leukemia
- Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
- Array BioPharma Presents Additional Positive Phase 1 Results in Two Programs at the 2008 Annual European Congress of Rheumatology
- Carbocisteine Can Reduce Worsening of COPD
- Gilead Announces Interim 12-Month Phase III Study Results for Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
- VIVUS Announces Presentation of Qnexa Data at the 2008 BIO International Convention
- Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
- Transave Announces Positive Phase II Results for Once-Daily Arikace in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
- SIR-Spheres Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting
- Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia
- SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
- Study of Vidaza in Higher-Risk Patients with Myelodysplastic Syndromes Reports Improved Overall Survival
- Vidaza Continues to Show Significant Overall Survival Benefit When Compared with Conventional Care Regimens Across the EU
- Data from Phase II Exploratory Study Suggest That Orencia (abatacept) May Delay Development of Rheumatoid Arthritis in Adults with Undifferentiated Inflammatory Arthritis
- Data Presented at the 13th Congress of the European Hematology Association Demonstrate Advances in the Treatment of Patients with High-Risk Myelodysplastic Syndromes
June 16, 2008
- Vical Pandemic Influenza Vaccines Provide Complete Protection in Animal Studies; The Journal of Infectious Diseases Publishes H5N1 Challenge Data
- NanoViricides Anti-HIV Lead Drug Candidate Demonstrated Substantial Improvement in Survival Time in Animal Model
- Antisoma plc (UK) - Antisoma announces AS1413 (Xanafide) presentation at EHA
- ChemGenex’s Omacetaxine Demonstrates Activity in CML Patients Who Have Failed Therapy with Multiple Tyrosine Kinase Inhibitors
- Soliris Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
- ChemGenex's Omacetaxine Demonstrates Activity in CML Patients Who Have Failed Therapy With Multiple Tyrosine Kinase Inhibitors
- Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
- ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
- Romiplostim Data Show Potential Long-Term Efficacy and Safety in Adults with Chronic ITP
- Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
- Adventrx Announces CoFactor Phase 2b Clinical Trial Overall Survival Results
- SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation
- Bionovo's Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
- Teva's Azilect 1 mg Tablets Meet End Points in ADAGIO Phase III Trial
- Gentronix Use Abcellute Preserved Hepatocytes to Enhance in Vitro Genotoxicity Testing
- Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting
- Sensitivity Enhancements to Monogram's Trofile Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
- Bionovo's Drug Candidate Shows In Vivo Safety and Efficacy in the Treatment of Vaginal Atrophy
- Nextrials and Allon Therapeutics Set New Benchmark for Releasing Clinical Trial Results
- Journal of Drugs in Dermatology Highlights Data Showing the Benefits of Solubilized 5% Benzoyl Peroxide Gel in the Treatment of Acne
- Molecular Insight Pharmaceuticals, Inc. Reports Preclinical Data on Solazed for Treatment of Metastatic Melanoma at Society of Nuclear Medicine (SNM) Meeting
- Novelos Therapeutics and MUSC Peer Reviewed Article Published in Expert Opinion on Investigational Drugs
- Quatrx Pharmaceuticals Presents Results From Ophena (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
- Neuromonics Announces Publication of Controlled Tinnitus Treatment Study
- US WorldMeds Completes Phase III Trial of Lofexidine for Treatment of Opiate Withdrawal Symptoms
- Data from Overseas Phase III Trial (RADIATE and AMBITION) Demonstrates Efficacy of "Actemra," a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in Rheumatoid Arthritis Patients
- New Study Shows Benicar (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
- Revlimid Data for Newly Diagnosed Multiple Myeloma Reported at a Satellite Symposium During the 13th European Hematology Association Congress
- VaxInnate to Discuss Seasonal and Pandemic Flu Vaccines During BIO 2008 This Week
- More Than Two-Thirds of Newly-Diagnosed Patients Who Are Prescribed Medications for OCD Receive Inadequate Therapy
- Pharming announces positive results from North American randomized trial with rhucin
- Tercica Announces Results from Increlex IGFD Patient Registry and Other Increlex Studies at the 90th Meeting of the Endocrine Society
- BaroFold Inc. Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron
- Preterax Prevents / Regresses Kidney Disease in Diabetics in Addition to Life-saving Benefits
June 17, 2008
- Akesis Pharmaceuticals Reports Positive Results from its Phase IIa Trial of AKP-020 for Type 2 Diabetes
- Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
- Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease
- Clinical Data For Revlimid And Vidaza In Important Blood Cancers Presented at The 13th European Hematology Association Congress
- PLx Pharma Demonstrates Bioequivalence with Aspirin and PL 2100 -- Aspirin-PC
- Lytix Reveals Further Details on First Cancer Candidate Oncopore at BIO2008
- Elan and Wyeth Announce Encouraging Top-line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease
- Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for Endometriosis
- Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
- Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study
- invivodata Captures Primary Efficacy Data in Largest Controlled Allergy Vaccine Trial
- Osteologix to Present a Corporate Overview and Phase 2 Osteoporosis Data at the BIO International Conference
- TransMolecular Presents Imaging and Pharmacokinetic Analysis of (131)Iodine-TM601 at Society for Nuclear Medicine Meeting
- Lantheus Medical Imaging Presents Phase I Study Results of Novel PET Myocardial Perfusion Imaging Tracer
- Long-Term Safety Data on Lialda (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
- Gloucester Pharmaceuticals Announces Phase 2 Data for Romidepsin Showing Durable Response in Refractory CTCL
- Effective Communication of Clinical Studies for Maximum Impact
- Accentia Reports on Multiple Sclerosis Study: Revimmune Shows Unprecedented Results in Reducing Disability and Improving Functions
- Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
June 18, 2008
- Panacos Announces Results of Bevirimat Prospective Study, which Confirm Patient Response Predictors
- New Subset Analysis of AndroGel Data Highlights Efficacy - Regardless of BMI
- Cytopia To Present Data on FMS Program With Anticancer Potential
- EG011 (Refractory Angina) Demonstrates Ability to Grow New Blood Vessels and Restore Heart Function Following Heart Attack
- Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in Blood Pressure with CVRx Rheos Hypertension Therapy
- Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection
- Avontec Announces Results of a Multiple Dose Clinical Phase I Study with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment in Male Healthy Volunteers
- Theratechnologies Reports Positive 26-week Results for Its Second Tesamorelin Phase 3 Trial
- Micardis-Based Regimens Help More Patients Achieve Their Blood Pressure Goals
- Molecular Insight Pharmaceuticals, Inc. Presents Three Studies on Trofex Program for Prostate Cancer Diagnosis and Staging
- Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting
- Molecular Insight Pharmaceuticals, Inc. Reports Onalta Tissue Distribution Data Support Clinical Development Program
- Nventa Develops Proprietary Vaccine Adjuvant
- Cortex and Top Alberta Government Officials Meet to Discuss Progress on Ampakine Compounds at the 2008 Bio Conference
- Biotie's VAP-1 Antibody Program to Proceed to Clinical Studies in Rheumatoid Arthritis and Psoriasis Patients
- Kidney Transplant Patients May Benefit from Going Off of Certain Immunosuppressive Drugs
June 19, 2008
- Patient's Own Infection-Fighting T Cells Put Late-Stage Melanoma Into Long-Term Remission - Without Chemotherapy or Radiation
- Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
- Metabasis Announces Promising Results from Its Phase 1b Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
- Bavarian Nordic Reports Interim Data from Phase I/II Studies with Breast Cancer Vaccine
- Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
- CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
- Oncolin Therapeutics Announces Its Cancer Technology Will Be Presented at the 20th EORTC-NCI-AACR Symposium
- Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
- Generex Biotechnology Corporation to Hold Conference Call on Tuesday, June 24th to Update Investors on Phase III Trial of Generex Oral-lyn and Other Corporate Activities
- Speedel Reports on Data Published at Hypertension 2008 Medical Congress
- Published Study Reveals Next Pharmaceuticals' Flavoxine Reduces Multiple Heart Health Risk Factors Including High Cholesterol
- Weight Gain Within the Normal Range Increases Risk of Chronic Kidney Disease
June 20, 2008
- EPIX Pharmaceuticals to Present at the Eighth Annual Structure-Based Drug Design Conference
- Controlling Perioperative Hypertension with Cleviprex Reduces Risk of Heart Attack and of Death Following Cardiac Surgery, According to New Analyses
- Active Biotech's Novel MS Compound Laquinimod Featured in the Scientific Publication The Lancet
- Pivotal Pulmonary Arterial Hypertension Study Published in the Lancet Concludes That Bosentan (tracleer) Demonstrates Benefits in Patients with Mildly Symptomatic WHO Functional Class II Disease
- Generex Biotechnology Presented Data at The Endocrine Society's Annual Meeting
- Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
- New Data Show Merck's Rotateq Helped Reduce Hospitalizations and Emergency Room Visits Due to Rotavirus Gastroenteritis for up to Three Years after Vaccination
- Zebinix a New Anti-epileptic Drug That Offers Hope to Epilepsy Sufferers Major Phase III Study Data Released
June 23, 2008
- Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
- Stroke Study Reveals a Key Target For Improving Treatment
- Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
- Tranzyme Pharma Announces Successful Thorough QT/QTc Study of Ghrelin Agonist TZP-101
- Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
- A Shot in the Arm Against Breast Cancer
- PREPARED Study Demonstrates Requip-Modutab Is a Highly Effective Treatment in the Management of Parkinson's Disease
- Management of High Blood Pressure Immediately After Stroke
- Study Shows That Small Protein Can Broaden Immune Response in Humans
- TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
- Research and Markets: Determine the Impact of the ENHANCE Study on Vytorin and Zetia Use
June 24, 2008
- CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
- Akesis Pharmaceuticals and Charles River Laboratories to Begin 13-Week Animal Study for AKP- 020
- RhuDex Achieves Positive Results in Clinical Phase IIa Trial
- MediGene Achieves Positive Results with RhuDex in Clinical Phase IIa Trial
- Genta Updates Progress of its Phase 3 Trial of Genasense in Patients with Advanced Melanoma
- Phase I Intravenous Trial for Melanoma, Prostate and Breast Cancer – Cohort Complete
- Independent Clinical Trial Investigators To Present New Data on Nymox's NX-1207 Drug in Development For Benign Prostatic Hyperplasia
- Titan Pharmaceuticals Announces Spheramine Presentations at 12th International Congress of Parkinson's Disease and Movement Disorders
- First Results for Phase IIa Data of UCB's Lacosamide for Treatment of Fibromyalgia
June 25, 2008
- Nerve Cells Derived from Embryonic Stem Cells and Transplanted into Mice May Lead to Improved Brain Treatments
- VGX Announces Publication of Preclinical Data for the Company's Avian Flu Vaccine Candidate in PLoS ONE Journal
- The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
- Immutep Reports that LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy in Preclinical Studies
- Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
- Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
- TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
- Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
- First Comprehensive Report on Colorectal Cancer (CRC) Care in Europe and Australia Reveals Urgent Need for Action
- Clavis Pharma ASA Announces Promising Results for Oral CP-4126
- High Levels of Urinary Albumin in the Normal Range Predict Hypertension
June 26, 2008
- Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
- Results from ValiRx in the Epigenetics Field Announced Below
- Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur FA Study
- Radiesse Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers
- Promising In Vivo Data for VAL 101 Compound Targets Pancreatic Cancer, based on GeneICE Gene Silencing Technology
- VIVUS Announces New Data from Qnexa Diabetes Study
- Cytheris Announces Publication of IL-7 Oncology Data in The Journal of Experimental Medicine
- NeuroSearch Successfully Completes Phase I with ACR325 And Announces the Decision to Progress Development into Phase II Proof-of-Concept Studies in Parkinson’s disease and Bipolar Disorder
- Avastin Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation
- Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
- Anavex Life Sciences Corp. will Present New Findings at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA)
- Zysolin Improves Survival in Pivotal Animal Studies
- pSivida Announces Interim Results from the Three-Month Readout of the Human PK Medidur FA Study
- New England Journal of Medicine Publishes Results from Two of the Landmark Phase III RECORD Studies with Rivaroxaban
- iCo Therapeutics Reports New iCo-009 (Oral Amphotericin B) Preclinical Results
- Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report
June 27, 2008
- New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix (Panitumumab)
- New England Journal of Medicine and the Lancet Publish Results from Landmark Rivaroxaban Studies
- Optimer Reports Additional Data on Investigational Compound OPT-80 at Anaerobe 2008 Congress
- Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III Study
- Data Show Significantly More Patients Were Pain-Free with Treximet (sumatriptan and naproxen sodium) Tablets in the Acute Treatment of Probable Migraine Without Aura in Adults
- Treximet (sumatriptan and naproxen sodium) Tablets Shown to be Effective in Patients Who Previously Had Poor Response to, or Did Not Tolerate, Migraine Treatment with a Short-Acting Triptan
- Liver Phase I Results Presented at WCIO 2008 & Best of ASCO
- Combination Therapy: A Real Advance for Cancer Patients with Follicular Lymphoma
- International Team Locates Key Player in Muscle Regeneration
June 30, 2008
- Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan in Alzheimer's Disease
- MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
- Zogenix Announces Clinical Study Results for Sumatriptan DosePro, a Novel Migraine Treatment
- Teva & ANP Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction in Disease Activity
- Oncolin Therapeutics Announces the Discovery of a New More Effective Anti-Cancer Treatment in Experimental Brain Tumor Models
- Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
- Early Results from Ongoing Clinical Study of Hepatitis C Vaccine Delivered by Inovio Biomedical's Electroporation System Show Increased T-Cell Responses and Reduced Viral Loads
- ThromboGenics Announces Positive Results from its Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
- Aradigm Reports Successful Top-line Phase 2 Data with Inhaled Liposomal Ciprofloxacin for Cystic Fibrosis
- Erbitux – Enhanced Efficacy Demonstrated in Patients With KRAS Wild-Type Tumors in 1st-Line Metastatic Colorectal Cancer
- The GI Company Reports Additional Phase II Clinical Data for Oral Mucositis
- DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix or Aspirin
- Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel
- Results of Flurizan in Clinical Phase III Trial
- Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
- Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death
- Isis Pharmaceuticals Conference Call Notice
- Phase II Results for Low-Dose Oral Immune Tolerance Therapy (ARG201) in Systemic Scleroderma Published
- NuPathe Reports Positive Phase I Results for NP101, a Novel Transdermal Patch for Acute Migraine
